Fractionated high-dose-rate and pulsed-dose-rate brachytherapy: First clinical experience in squamous cell carcinoma of the tonsillar fossa and soft palate

Levendag, Peter C.; Schmitz, Paul; Jansen, Peter P.; Senan, Suresh; Eijkenboom, W. M. H.; Sipkema, Dick; Meeuwis, Cees A.; Kolkman-Deurloo, Inger Karine; Visser, A.G.

doi:10.1016/s0360-3016(97)00046-1

Cited by 89 publications

(49 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This was also observed in a study using fractionated high-dose-rate and pulsed-doserate brachytherapy regimens, which simulate classical continuous low-dose-rate interstitial radiation therapy schedules (28).…”

Section: Discussionsupporting

confidence: 53%

Squamous Cell Carcinoma of the Oropharynx-An Analysis of Treatment Results in 289 Consecutive Patients

Johansen

Grau²,

Overgaard

2000

Acta Oncologica

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 53%

Squamous Cell Carcinoma of the Oropharynx-An Analysis of Treatment Results in 289 Consecutive Patients

Johansen

Grau²,

Overgaard

2000

Acta Oncologica

View full text Add to dashboard Cite

“…At Rotterdam, 77 patients were treated with IMRT (n = 37), threedimensional conformal RT (n = 22), or computed tomography-based parallel-opposed beam techniques. In 52% of the patients, BT was used according to previously detailed methods (4,5). Additional details regarding the treatment methods used in Rotterdam have been previously published (6).…”

Section: Patients and Therapymentioning

confidence: 99%

“…At Erasmus Medical Center in Rotterdam, brachytherapy (BT) has been used for many years as a tool to facilitate the delivery of a high tumor dose (4,5). BT substantially reduces the doses delivered to neighboring tissues, specifically the neighboring swallowing structures, compared with conventional RT.…”

Section: Introductionmentioning

confidence: 99%

Can IMRT or Brachytherapy Reduce Dysphagia Associated With Chemoradiotherapy of Head and Neck Cancer? The Michigan and Rotterdam Experiences

Eisbruch

Levendag

Feng

et al. 2007

International Journal of Radiation Oncology*Biology*Physics

Self Cite

View full text Add to dashboard Cite

Purpose-Dysphagia is a major late complication of intensive chemoradiotherapy of head and neck cancer. The initial clinical results of intensity-modulated radiotherapy (IMRT), or brachytherapy, planned specifically to reduce dysphagia are presented.Patients and Methods-Previous research at Michigan University has suggested that the pharyngeal constrictors and glottic and supraglottic larynx are likely structures whose damage by chemo-RT causes dysphagia and aspiration. In a prospective Michigan trial, 36 patients with oropharyngeal (n = 31) or nasopharyngeal (n = 5) cancer underwent chemo-IMRT. IMRT cost functions included sparing noninvolved pharyngeal constrictors and the glottic and supraglottic larynx. After a review of published studies, the retropharyngeal nodes at risk were defined as the lateral, but not the medial, retropharyngeal nodes, which facilitated sparing of the swallowing structures. In Rotterdam, 77 patients with oropharyngeal cancer were treated with IMRT, three dimensional RT, or conventional RT; also one-half received brachytherapy. The dysphagia endpoints included videofluoroscopy and observer-assessed scores at Michigan and patient-reported qualityof-life instruments in both studies.Results-In both studies, the doses to the upper and middle constrictors correlated highly with the dysphagia endpoints. In addition, doses to the glottic and supraglottic larynx were significant in the Michigan series. In the Rotterdam series, brachytherapy (which reduced the doses to the swallowing structures) was the only significant factor on multivariate analysis. Conclusion-The dose-response relationships for the swallowing structures found in these studies suggest that reducing their doses, using either IMRT aimed at their sparing, or brachytherapy, might achieve clinical gains in dysphagia.

show abstract

“…Levendag et al treated 38 patients presenting with T1-4 squamous cell carcinoma of the tonsillar fossa and soft palate with a combination of external beam radiation therapy and a boost with HDR or PDR brachytherapy (40). Three-year local relapse-free survival was approximately 90%, and seems comparable to that obtained with LDR brachytherapy.…”

Section: High Dose Rate Brachytherapymentioning

confidence: 95%

How to Optimize Therapeutic Ratio in Brachytherapy of Head and Neck Squamous Cell Carcinoma?

Mazeron¹,

Gerbaulet²,

Simon³

et al. 1998

Acta Oncologica

View full text Add to dashboard Cite

Fractionated high-dose-rate and pulsed-dose-rate brachytherapy: First clinical experience in squamous cell carcinoma of the tonsillar fossa and soft palate

Cited by 89 publications

References 22 publications

Squamous Cell Carcinoma of the Oropharynx-An Analysis of Treatment Results in 289 Consecutive Patients

Squamous Cell Carcinoma of the Oropharynx-An Analysis of Treatment Results in 289 Consecutive Patients

Can IMRT or Brachytherapy Reduce Dysphagia Associated With Chemoradiotherapy of Head and Neck Cancer? The Michigan and Rotterdam Experiences

How to Optimize Therapeutic Ratio in Brachytherapy of Head and Neck Squamous Cell Carcinoma?

Contact Info

Product

Resources

About